Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

Qiagen deals for cancer biomarkers, 7/13:107

Qiagen announced two agreements that add biomarkers involving glioblastoma, lymphoma, and other cancers to the company’s portfolio of potential companion diagnostics. In the glioblastoma project, Qiagen has entered into an exclusive worldwide licensing option with Columbia University in New York on FGFR-TACC fusion genes. Qiagen intends to develop this biomarker into a test for routine use in diagnostic workups, which may allow doctors to identify glioblastoma patients who could benefit from targeted treatments.

Cardiovascular genetic testing, 7/13

Aviir Inc. is increasing its offered services with a comprehensive inherited cardiovascular disease genetic test menu. The newly validated tests cover the major causes of cardiomyopathies, arrhythmia disorders, and other genetically transmitted diseases that affect the heart and vasculature. Each test is available for individual and familial settings. Two comprehensive panels are available to check for undiagnosed arrhythmia or cardiomyopathy.

Biosearch acquires VitraBio, DNA Technology, 7/13:106

Biosearch Technologies has acquired the oligonucleotide manufacturing division of Danish company DNA Technology and the German CPG manufacturer VitraBio. With the acquisition of DNA Technology, Biosearch adds a skilled production team with a mature quality system and an established European customer base focused in the Nordic countries.

Automated system for nucleic acid extraction, 7/13:106

Hamilton Robotics has collaborated with Macherey-Nagel to create the Genomic Starlet automated liquid handling workstation. The system extracts nucleic acids from biological samples and purifies PCR products in a non-IVD environment.

CLIA waiver studies for HIV 1/2 assay, 7/13:106

Chembio Diagnostics has commenced CLIA waiver studies for its DPP HIV 1/2 assay. In December 2012, Chembio received FDA approval for its DPP HIV 1/2 assay, which detects antibodies to HIV 1/2 in oral fluid, fingerstick whole blood, venous whole blood, serum, or plasma samples.

Beckman Coulter, Illumina automate NGS applications, 7/13:106

Through a partnership with Illumina, Beckman Coulter Life Sciences will develop, distribute, and support automation for Illumina’s TruSeq and Nextera next-gen sequencing sample preparation kits. Illumina will provide technical expertise on chemistry and protocols.

Enhanced capability for molecular diagnostic system

Abbott has introduced a new capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient. Abbott’s mPlus makes it possible for laboratories to perform molecular diagnostic tests for infectious disease detection and therapy monitoring.

Aldosterone assay, 7/13:105

DiaSorin has received FDA clearance for its Liaison aldosterone immunoassay, which is intended for the quantitative determination of aldosterone in human serum, EDTA plasma, and urine samples. The test is used primarily for the diagnosis of hypertension.

ASI, WaveSense to provide imaging and analysis instrument and cell enrichment solution, 7/13:105

Applied Spectral Imaging and WaveSense have entered into an agreement in which both companies will engage in combined sales and marketing of ASI’s GenASIs imaging and analysis instrument and WaveSense’s EpiSep cell recovery and enrichment solution. The combined solution provides an integrated cell capturing solution and computerized instrument to detect, image, and analyze the captured cells.

CE Mark for HbA1c test

Abbott announced CE Marking for its Architect clinical chemistry hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.

MARKETPLACE

TRENDING